Human IL-2 (IL-2) is a potent pleiotropic cytokine approved for treatment of melanoma and renal cell carcinoma16, but its therapeutic potential is limited by preferential activation of CD25+ cells and severe dose-limiting toxicities associated with systemic IL-2 activity3. This evidence concerns the gene IL2 and melanoma.